Disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company, CURE Pharmaceutical, expects increased demand for its transdermal drug delivery platform that uses an epidermis penetration enhancer to increase delivery functionality.
High demand
The company’s transdermal drug delivery platform has been designed to transfer a therapeutically effective amount of drug across a patient’s skin. It works by using an epidermis penetration enhancer, a vasodilator, which opens pores sufficiently to allow active ingredients, combined with carrier solvents, to pass across the epidermis layer of the skin and into the dermis and subdermal tissue.
“Transdermal drug delivery is one of our proprietary drug delivery technologies that helps us support our mission to improve people’s lives by redefining how medicines and health products are delivered and experienced,” said CEO of CURE Rob Davidson. “We expect to experience increased demand for our transdermal products as consumers and the healthcare industry increasingly turn to drug delivery methods that result in improved drug delivery and medication compliance.”
A recent research report by Research and Markets has predicted that the global market of transdermal drug delivery will grow over the next ten years, reaching approximately $95.57 billion by 2025. This will represent a compound and annual growth rate of 11.6%.
Additionally, CURE is researching and developing proprietary formulas of different cannabinoids and terpene profiles integrated into its advanced oral thin film, CureFilm and transdermal applications leveraging its proprietary polymer and encapsulation technology. The Company is focusing on integrating its proprietary delivery systems to provide solutions to conditions like pain, neuropathy, cancer (including paediatric cancer), PTSD and other psychiatric disorders, autoimmune diseases, Parkinson’s disease and sleep disorders.